MR contrast developer Epix Medical has launched a multicenter trial evaluating its MS-325 blood pool contrast agent for high-resolution vessel imaging.
The goal of the study is to optimize high-resolution imaging with MS-325 as the first step in the characterization of vascular wall structures and vulnerable plaque, according to the Cambridge, MA-based firm.
By AuntMinnie.com staff writersJuly 8, 2004
Related Reading
Schering submits MS-325 for EU approval, June 7, 2004
Epix raises $96 million, June 4, 2004
Epix floats new debt, June 2, 2004
Schering gets Swedish approval for Primovist, April 5, 2004
Schering gets European OK for Zevalin for NHL, January 22, 2004
Copyright © 2004 AuntMinnie.com
